Abstract
We compared the incidence of clinical CMV illness in 25 renal transplant recipients treated with OKT3 for steroid resistant cellular rejection with 88 renal transplant patients treated only with conventional immunosuppression (cyclosporin A and steroids). Nine (36%) patients in the OKT3 group developed CMV illness compared to (2.3%) amongst those treated conventionally (p<0.0005). Patients who received OKT3 were divided into four groups according to the CMV antibody status of the donor and recipient. Six of the 9 episodes of CMV infection occurred in patients not previously exposed to CMV, who received a kidney from a CMV positive donor. Three (12%) of the patients treated with OKT3 died of CMV disease. A further 2 patients died of other causes giving an overall mortality in the OKT3 treated group of 20%. We concluded that when OKT3 therapy is used in association with donor/recipient CMV mismatch it is associated with a high CMV morbidity and mortality.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Son, E. J. Van. The Th. Cytomegalovirus infection after organ transplantation: an update with special emphasis on renal transplantation. Transplant Int. 1989: 2, 147–164.
Simmonds, R., Lopez, C., Balfour, H., Kalis, J., Rattazzi, L., Majarian, J. Cytomegalovirus: Clinical virological correlations in renal transplant recipients. Ann. Surg. 1974: 180, 623–632.
Kurtz, J. B., Thompson, J. F., Ting, A., Pinto, A., Morris, P. J. The problem of cytomegalovirus infection in renal allograft recipients. Quarterly Journal of Medicine 1984: 211, 341–349.
Fryd, D., Peterson, P., Ferguson, R., Simmons, R., Balfour, H., Najarian, J. Cytomegalovirus as a risk factor in renal transplantation. Transplantation 1980: 30, 436–439.
Lewis, R., Johnson, P., Golden, D., Buren, C. van, Kerman, R., Kahan, B. The adverse impact of Cytomegalovirus infection on clinical outcome in Cyclosporin-Prednisone treated renal allograft recipients. Transplantation 1988: 45, 353–359.
Smiley, M. L., Wlodavir, C. G., Grosmann, R. A., Barker, C. F., Perloff, L. J., Trustin, N. B., Starr, S. E.et al. The role of pretransplant immunity in protection from cytomegalovirus disease following renal transplantation. Transplantation 1985: 40, 157–161.
Velasco, N., Catto, G. R. D., Edward, N., Engest, J.et al. The effect of the dosage of steroids on the incidence of cytomegalovirus infections in renal transplant recipients. J. Infect. Dis. 1982: 2, 69–78.
Reynolds, D. W., Stango, S., Alford, C. A. Laboratory diagnosis of cytomegalovirus infections. In: diagnostic procedures for viral, ricketsial and chlamydial infections. Washington CD, American Public Association, 1979: 399–439.
Norman, D. J., Shield, C. F., Bary, J., Funnell, M. B., Lemmon, J. A US clinical study of orthoclone OKT3 in renal transplantation. Transplant-Proc. 1987: 19 (2 Suppl. 1), 21–27.
Choohng-Sah, Oh, Stratta, R. J., Fox, B. C, Sollonger, H. W., Beizer, F. O., Maki, D. G. Increased infections associated with the use of OKT3 for treatment of steroid resistant rejection in renal transplantation. Transplantation 1988: 45(1), 68–73.
Krech, U. H., Jung, M., Jung, F. Cytomegalovirus in man. Karger, Basel 1971: 1–105.
Chou, S., Norman, D. J. Effect of OKT3 antibody therapy on Cytomegalovirus reactivation in renal transplant recipients: Transplantation Proceedings 1987: 19(4), 3433–3434.
Winde, G., Died, K. H., Raidt, H., Bucholz, B., Lison, A. E., Bunte, H. Use of orthoclone OKT3 as treatment of acute renal allograft rejection and as first line therapy in kidney transplantation. Transplantation Proceedings 1988: 20(5), (Suppl. 6), 87–89.
Monaco, A., Goldstein, G., Barnes, L. Use of orthoclone OKT3 monoclonal antibody to reverse acute renal rejection unresponsive to treatment with conventional immunosuppressive regimens. Transplant Proc. 1987: 19 (2 Suppl. 1), 28–31.
Ludwin, D., White, N., Tsai, S., Chernesky, M., Achong, M., Smith, E. Results of prospective matching for cytomegalovirus status in renal transplant recipients. Transplantation Proceedings 1985: 17, 2755–1756.
Balfour, H., Chace, B., Stapleton, T., Simmons, R., Fryd, S. A randomised, placebo controlled trial of oral acyclovoir for the prevention of cytomegalovirus in recipients of renal allografts. New England J. Med. 1989: 329, 1381–1387.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Conlon, P.J., Carmody, M., Donohoe, J. et al. Cytomegalovirus infection as a complication of OKT3 therapy in kidney transplant recipients. I.J.M.S. 161, 630–632 (1992). https://doi.org/10.1007/BF02983769
Issue Date:
DOI: https://doi.org/10.1007/BF02983769